Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1427755
This article is part of the Research Topic New Drugs and Future Challenges in Drug Metabolism and Transport View all 13 articles

The efficacy and safety of Remimazolam besylate, Ciprofol, and Propofol during Hysteroscopy

Provisionally accepted
Weifeng Shan Weifeng Shan 1,2Shuying Gao Shuying Gao 1,2*Mengting Ai Mengting Ai 1,2*Haiyan Lan Haiyan Lan 1,2Gongchen Duan Gongchen Duan 1,2Xiaoli Dong Xiaoli Dong 1,2*Qiaomin Xu Qiaomin Xu 1,2Yini Wu Yini Wu 1,2*Jimin Wu Jimin Wu 1,2*
  • 1 Wenzhou Medical University, Wenzhou, China
  • 2 lishui hospital, Lishui, China

The final, formatted version of the article will be published soon.

    Objective: Remimazolam besylate and Ciprofol are newer sedatives used in minor surgeries. Propofol is a classic drug mainly used for short surgeries. This trial was conducted to compare the efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopic surgeries. Methods: Patients undergoing hysteroscopy were randomly assigned to receive remimazolam besylate (Group R), ciprofol (Group C), or propofol (Group P). A total of 194 patients were assessed for eligibility. One patient in Group P was excluded because the operation had timed out of 60min. Patients all in Group R、Group C and Group P received an induction dose of 0.2 mg/kg remimazolam besylate、0.4 mg/kg ciprofol、2.0 mg/kg propofol seperately over 30sec. A corresponding dosage of 1 mg/kg/h、0.6–1.2 mg/kg/h and 3.0–6.0 mg/kg/h was given by continuous intravenous infusion to maintain a BIS of 40–60 till the end of the surgery. The incidence rates of body movement, respiratory depression, and adverse effects were compared among the groups. Results: The incidence of injection pain was much higher in Group P (64.1%) than that in Group R (3.4%) and Group C (3.2%, both P < 0.001). The onset time was significantly shorter in Group P than that in Group R and Group C (both P < 0.01). The awakening time (MOAA/S score = 3) was longest in Group R, followed by Groups C and Group P (P < 0.01). The time to complete recovery (MOAA/S score = 5) has no significantly difference between Group C and Group P, whereas the onset time was significantly shorter in Group R (P < 0.01). The number of body movements was significantly higher in Group R than that in Group C and Group P (P < 0.01). The incidence of hypotension was significantly lower in Group R than that in Group C and Group P (both P < 0.01). The rate of respiratory inhibition was significantly lower in Group R and Group C than that in Group P (both P < 0.05). Conclusion: Considering jointly the safety and efficacy , ciprofol seems to be the best choice for sedation.

    Keywords: Remimazolam, Ciprofol, Propofol, Hysteroscopy, efficacy, Safety

    Received: 04 May 2024; Accepted: 13 Dec 2024.

    Copyright: © 2024 Shan, Gao, Ai, Lan, Duan, Dong, Xu, Wu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shuying Gao, Wenzhou Medical University, Wenzhou, China
    Mengting Ai, Wenzhou Medical University, Wenzhou, China
    Xiaoli Dong, Wenzhou Medical University, Wenzhou, China
    Yini Wu, Wenzhou Medical University, Wenzhou, China
    Jimin Wu, Wenzhou Medical University, Wenzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.